Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
- Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.Contraception. 2009; 80: 119-127
- Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review.Contraception. 2010; 82: 314-323
- The integration of pharmacokinetics and pharmacodynamics: understanding dose-response.Annu Rev Pharmacol Toxicol. 2004; 44: 111-136
- Predictors of noncompliance in an oral contraceptive clinical trial.Contraception. 2012; 85: 465-469
- Contraceptive Use in the United States.(July 2012. Accessed 9/28/2012, at)
- Continuation and compliance of contraceptive use.Eur J Contracept Reprod Health Care. 2002; 7: 178-183
- Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users.Contraception. 2012; 87: 220-226
- Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial.Obstet Gynecol. 2010; 116: 275-283
- WHO laboratory manual for the examination of human sperm and sperm-cervical mucus interaction.Cambridge University Press, Cambridge1992
- Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles.Infection. 2001; 29: 11-15
- Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women.Contraception. 2010; 81: 474-480
- NORPLANT: levonorgestrel-releasing contraceptive implant.Ann Med. 1993; 25: 155-160
- Clinical pharmacokinetics.Clin Pharmacokinet. 1995; 28: 203-215
- Pharmacokinetics of gestagens: some problems.Am J Obstet Gynecol. 1990; 163: 323-328
- Pharmacokinetics of single-dose levonorgestrel in adolescents.Contraception. 2006; 74: 104-109
- Synthesis and regulation of sex hormone-binding globulin in obesity.Int J Obes Relat Metab Disord. 2000; 24: S64-S70
- Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel.Contraception. 2011; 84: 363-367
- Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen.Obstet Gynecol. 2011; 117: 33-40
- Greater inhibition of pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval.Contraception. 2006; 74: 100-103
- Residual ovarian activity during oral steroid contraception.Hum Reprod Update. 2002; 8: 345-358
☆Clinical trials number: NCT01170390.
☆☆Authors Disclosures: Dr. Edelman: consultant for Gynuity Health Projects, Genzyme and Agile Therapeutics; Nexplanon trainer for Merck; and author for UptoDate (Royalties received). She receives research funding from the National Institute of Health and the Bill & Melinda Gates Foundation. These potential conflicts of interest have been reviewed and managed by Oregon Health & Science University (OHSU). Dr. Jensen has received payments for consulting from Bayer Healthcare, Merck, Agile Therapeutics, HRA Pharma and the Population Council and for giving talks for Bayer and Merck. He has also received research funding from Abbott Pharmaceuticals, Bayer, the Population Council, the National Institute of Health and the Bill & Melinda Gates Foundation. These companies and organizations may have a commercial or financial interest in the results of this research and technology. These potential conflicts of interest have been reviewed and managed by OHSU. Dr. Stanczyk is presently on the advisory board for Merck & Co., Inc. and Agile Therapeutics. Also, in the last few years, he has consulted for Shionogi Inc. and Bayer Healthcare. Ms. McInnis and Drs. Munar and Cherala have no disclosures.
★Financial Support: The authors acknowledge the grant support from the National Institutes of Health (R01 HD061582-01 NICHD; 2K12HD043488 NICHD), the OHSU Oregon Clinical & Translational Research Institute (NIH NCRR 1 UL1 RR024120) and the Bioanalytical Shared Resource/Pharmacokinetics Core at OHSU.